Association of Chronic Hepatitis C Infection Related Depression, Anxiety, and Neurocognitive Performance Achieving SVR-12 with Direct-Acting Antivirals: A Prospective Cohort Study

2021 ◽  
Author(s):  
Harmanpreet Kaur ◽  
Radha K. Dhiman ◽  
Anand V. Kulkarni ◽  
Madhumita Premkumar ◽  
Virendra Singh ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Direct Acting Antivirals ◽  
Neurocognitive Performance ◽  
Hepatitis C Infection ◽  
Direct Acting

scholarly journals Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e026703 ◽  
Author(s):  
Chung-Feng Huang ◽  
Ming-Lun Yeh ◽  
Ching-I Huang ◽  
Po-Cheng Liang ◽  
Yi-Hung Lin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Treatment Efficacy ◽  
Prospective Cohort ◽  
Direct Acting Antivirals ◽  
Svr12 Rate ◽  
Direct Acting

ObjectiveThe treatment outcome of direct-acting antivirals (DAAs) in chronic hepatitis C patients with hepatocellular carcinoma (HCC) is controversial. The current study aimed to address the treatment efficacy and safety of DAAs in patients with curative or active HCC, compared with those of patients without HCC.DesignA prospective cohort studySettingA medical centre and two regional hospitals in TaiwanParticipantsA total of 713 Taiwanese patients (601 non-HCC, 74 curative HCC and 38 active HCC patients) who received standard-of-care DAAs were consecutively enrolled in the study.Main outcome measurementThe primary objective was to determine treatment efficacy, defined as undetectable hepatitis C virus RNA throughout 12 weeks of the post-treatment follow-up period (sustained virological response 12 [SVR12]).ResultsThe overall SVR12 rate was 96.9%. The SVR12 rate was similar between the patients with HCC and those without HCC (95.5% vs 97.2%, p=0.37). The HCC patients were divided into two groups, those with curative HCC and those with viable HCC; a substantially but not significantly lower SVR rate, 92.1% (35/38), was observed in the patients with viable HCC compared with the SVR rate, 97.3% (72/74), in those with curative HCC (p=0.33). Compared with the patients with curative HCC, the patients with viable HCC had a significantly higher proportion of serious adverse events (10.5% vs 1.0%, p=0.002), early treatment discontinuation (10.5% vs 2.8%, p=0.03) and mortality (5.3% vs 0.1%, p=0.008).ConclusionsAn equivalently high SVR rate was observed in patients with either past or active HCC compared with those without HCC. The safety concerns in the HCC patients did not compromise treatment efficacy.

scholarly journals Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

The Lancet ◽  
2019 ◽  
Vol 393 (10179) ◽  
pp. 1453-1464 ◽  
Author(s):  
Fabrice Carrat ◽  
Hélène Fontaine ◽  
Céline Dorival ◽  
Mélanie Simony ◽  
Alpha Diallo ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Clinical Outcomes ◽  
Chronic Hepatitis C ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection

2012 ◽  
Vol 8 (1) ◽  
pp. e1002339 ◽  
Author(s):  
Bambang S. Adiwijaya ◽  
Tara L. Kieffer ◽  
Joshua Henshaw ◽  
Karen Eisenhauer ◽  
Holly Kimko ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Dynamic Model ◽  
Chronic Hepatitis C ◽  
Direct Acting Antivirals ◽  
Hepatitis C Infection ◽  
Treatment Regimens ◽  
Viral Dynamic ◽  
Direct Acting

scholarly journals The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study

2018 ◽  
Vol 7 (3) ◽  
pp. 373-385 ◽  
Author(s):  
Patricia A. M. Kracht ◽  
Faydra I. Lieveld ◽  
Linde M. Amelung ◽  
Carina J. R. Verstraete ◽  
Eveline P. Mauser-Bunschoten ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Patient Reported Outcomes ◽  
Direct Acting Antivirals ◽  
Patient Reported ◽  
Direct Acting ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document